{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:33:39Z","timestamp":1777718019944,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:00:00Z","timestamp":1339459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2012,8]]},"abstract":"<jats:p>Prasugrel, a thienopyridine ADP receptor antagonist, is an orally administered prodrug requiring in vivo metabolism to form the active metabolite that irreversibly inhibits platelet activation and aggregation mediated by the P2Y12[sub 12] receptor. A comprehensive nonclinical safety assessment including genotoxicity and carcinogenicity studies supported the chronic use of prasugrel in patients with atherothrombotic disease. In addition, a special assessment of the potential for prasugrel to enhance tumor growth was undertaken to address regulatory concerns relating to increases in human cancers. Prasugrel demonstrated no evidence of genotoxicity and was not oncogenic in a 2-year rat carcinogenicity study. In the 2-year mouse study, an increase in hepatocellular adenomas was considered secondary to enzyme induction and not relevant to human safety. Further, the absence of any increase in common background tumors at any other organ site in either rodent study indicated a lack of tumor promoting activity (apart from the CYP450 induction-related increase in mouse liver tumors). Cell culture studies with 3 human tumor cell lines (lung, colon, prostate) demonstrated that exposure of serum-starved cells to prasugrel's active and major circulating human metabolites does not increase cell proliferation relative to starved cells stimulated to proliferate by addition of 10% FBS. Prasugrel also did not increase tumor growth relative to vehicle controls in nude mice implanted with 3 human tumor cell lines. Thus, traditional genotoxicity and 2-year bioassays as well as specially designed tumor growth enhancement studies in human tumor cell lines and mouse xenograft models clearly demonstrated prasugrel's lack of tumorigenic potential.<\/jats:p>","DOI":"10.1177\/1091581812445073","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T01:33:56Z","timestamp":1339551236000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Nonclinical Assessment of Carcinogenic Risk and Tumor Growth Enhancement Potential of Prasugrel, a Platelet-Inhibiting Therapeutic Agent"],"prefix":"10.1177","volume":"31","author":[{"given":"Lorrene A.","family":"Buckley","sequence":"first","affiliation":[{"name":"Eli Lilly & Company, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sanbuissho","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Starling","sequence":"additional","affiliation":[{"name":"Eli Lilly & Company, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Pat","family":"Knadler","sequence":"additional","affiliation":[{"name":"Eli Lilly & Company, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip W.","family":"Iversen","sequence":"additional","affiliation":[{"name":"Eli Lilly & Company, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph A.","family":"Jakubowski","sequence":"additional","affiliation":[{"name":"Eli Lilly & Company, Indianapolis, IN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,6,12]]},"reference":[{"key":"bibr1-1091581812445073","unstructured":"US Food and Drug Administration. EFFIENT\u2122 Summary Review (NDA 22-307). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022307s000_SumR.pdf.2009. Accessed April 20, 2012."},{"key":"bibr2-1091581812445073","unstructured":"European Medicines Agency. European Public Assessment Report (EPAR) of Efient. EMEA\/H\/C\/984. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000984\/human_med_000756.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d124.2009. Accessed April 20, 2012."},{"key":"bibr3-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0907122"},{"key":"bibr4-1091581812445073","unstructured":"International conference on harmonisation guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. S2(R1). http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Safety\/S2_R1\/Step4\/S2R1_Step4.pdf2011. Accessed April 20, 2012."},{"key":"bibr5-1091581812445073","unstructured":"International conference on harmonisation dose selection for carcinogenicity studies of pharmaceuticals.S1C(R2). http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Safety\/S1C_R2\/Step4\/S1C_R2__Guideline.pdf2008. Accessed April 20, 2012."},{"key":"bibr6-1091581812445073","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry (DRAFT), Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals, Subsection IV C.6. 2001. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM079272.pdf Accessed April 20, 2012."},{"key":"bibr7-1091581812445073","unstructured":"Peto R, Pike MC, Day NE, Guidelines for Simple, Sensitive Significance Tests for Carcinogenic Effects in Long-term Animal Experiments, in Long-term and Short-term Screening Assays for Carcinogens: A Critical Appraisal. Lyon: World Health Organization; 1980;311\u2013426."},{"key":"bibr8-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.2813"},{"key":"bibr9-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-330220-5.50019-X"},{"key":"bibr10-1091581812445073","first-page":"25","volume-title":"Carcinogenesis","author":"Huff JE","year":"1994"},{"issue":"6","key":"bibr11-1091581812445073","first-page":"2151","volume":"41","author":"Feldman D","year":"1981","journal-title":"Cancer Res"},{"key":"bibr12-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(96)00067-8"},{"key":"bibr13-1091581812445073","first-page":"723","volume-title":"Handbook of Toxicologic Pathology","author":"Capen CC","year":"1991"},{"key":"bibr14-1091581812445073","first-page":"345","volume-title":"Mouse Liver Carcinogenesis: Mechanisms and Species Comparisons","author":"McClain RM","year":"1990"},{"key":"bibr15-1091581812445073","first-page":"125","volume-title":"Pathology of the Mouse","author":"Harada T","year":"1999"},{"key":"bibr16-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfj001"},{"key":"bibr17-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2012.01.014"},{"key":"bibr18-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)91505-8"},{"issue":"1","key":"bibr19-1091581812445073","first-page":"83","volume":"77","author":"Shirts SB","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"bibr20-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/81.10.803"},{"key":"bibr21-1091581812445073","volume-title":"Casarett & Doull's Toxicology: The Basic Science of Poisons","author":"Pito HC","year":"2001","edition":"6"},{"key":"bibr22-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-327007"},{"key":"bibr23-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706013"},{"key":"bibr24-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2004.02339.x"},{"key":"bibr25-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705639"},{"key":"bibr26-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2007.05741.x"},{"key":"bibr27-1091581812445073","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2006.060653"},{"key":"bibr28-1091581812445073","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.098384"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581812445073","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1091581812445073","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1091581812445073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:24:00Z","timestamp":1777458240000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1091581812445073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,12]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["10.1177\/1091581812445073"],"URL":"https:\/\/doi.org\/10.1177\/1091581812445073","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,12]]}}}